[7] Lambein K, Van Bockstal M, Vandemaele L, et al. Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance. Am J Clin Pathol. 2013 Oct;140(4)...
为了指导LM患者的治疗决策,临床医生可以考虑预后居里评分(Curie score),该评分综合了体能状态、LM诊断前接受化疗(CT)方案的数量和激素受体状态;对于来源于BC的LM患者,乳腺分级预后评估(Breast-GPA)在BC脑转移(BCBM)患者中得到验证。其它预后因素包括对治疗的初始反应和诊断时脑脊液(CSF)中的蛋白水平。需要注意的是,尽...
A score of 0or 1+ is considered Her2-negative, while a score of 3+ is considered Her2-positive. However, a score of 2+ is considered equivocal and requires further testing. For cases with equivocal IHC results (2+), additional testing using fluorescence in situ hybridization (FISH) or sil...
[2]Prat A,Guarneri V,ParéL,et al.A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer:a retrospective study with an external evaluation.Lancet Oncol.2020 Nov;21(11):1455-1464. [3]Sanna,G.et al.Brain metastases in patients with advanced breast...
A score of 0 or 1+ indicates negative HER2 expression, while a score of 3+ indicates positive HER2 expression. A score of 2+ is considered equivocal and requires further testing using FISH. In FISH testing, gene amplification is assessed by comparing the ratio of HER2 gene copies to ...
H评分是一种半定量方法,用于评估蛋白质或受体的表达强度,以及指示个体表达程度的细胞数量。基于文献数据使用了两个分界值:H-Score:低于50或低于75代表ER和PR表达阴性。 Allred评分也用于识别ER和PR的表达。0-6分描述阳性核染色的肿瘤细胞比例—A (0=无;...
有研究对 4 种 PR 抗体(1E2、EP2、SP2、16)免疫组化染色及比较,显示兔单克隆抗体 1E2平均着色细胞数、平均百分比评分、平均染色强度、平均 A-score 明显高于其他 3 个抗体,是较理想的 PR 抗体。 3、HER2 人表皮生长因子受体家族包括4位成员——HER1、HER2、HER3和HER4。作为跨膜蛋白,它们可以在细胞表面与...
A score of 0 or 1+ indicates no or low expression of Her2, while a score of 2+ is considered equivocal and requiresfurther testing. A score of 3+ indicates high expression of Her2. FISH is a molecular technique that examines the genetic material of tumor cells to determine the presence ...
图3 MONALEESA-7 研究绝经前 HR+/HER2- 晚期乳腺癌患者 OS 获益显著高于安慰剂组 同时,瑞波西利联合治疗的总体安全性良好,因不良事件(AE)导致的停药率显著较低(4%)[12]。瑞波西利可快速、高效、持久地缓解疼痛症状:治疗第 8 周时即可快速缓解疼痛症状[13],降低疼痛症状恶化风险达 35%[14],并持续缓解疼痛...
3、HER2与化疗：HER2阳性的乳腺癌患者容易对化疗耐药。含蒽环类药物的化疗方案对HER2阳性的乳腺癌患者带来更好的治疗反应性。4、基于HER2的其他治疗方法：拉帕替尼是继曲妥珠单抗后的另一个乳腺癌分子靶向药物，是一种酪氨酸激酶抑制剂，可同时抑制表皮生长因子受体和HER2受体酪氨酸激酶。乳腺癌替代的分子分类IHC标记 ?